Insider Buying: Alzamend Neuro, Inc. (NASDAQ:ALZN) Major Shareholder Purchases 50,000 Shares of Stock

Alzamend Neuro, Inc. (NASDAQ:ALZN – Get Rating) major shareholder Milton C. Ault III purchased 50,000 shares of Alzamend Neuro stock in a transaction that occurred on Monday, April 11th. The stock was acquired at an average price of $1.13 per share, for a total transaction of $56,500.00. Following the transaction, the insider now directly owns 150,000 shares of the company’s stock, valued at approximately $169,500. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Shares of ALZN opened at $1.02 on Wednesday. The company’s fifty day moving average is $1.20 and its 200 day moving average is $1.82. Alzamend Neuro, Inc. has a fifty-two week low of $0.88 and a fifty-two week high of $33.55.

Alzamend Neuro (NASDAQ:ALZN – Get Rating) last posted its quarterly earnings data on Tuesday, March 15th. The company reported ($0.03) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.03). As a group, analysts anticipate that Alzamend Neuro, Inc. will post -0.12 EPS for the current year.

A number of hedge funds have recently bought and sold shares of the business. Virtu Financial LLC bought a new position in Alzamend Neuro during the fourth quarter valued at $44,000. Marshall Wace LLP bought a new position in Alzamend Neuro during the fourth quarter valued at $313,000. Millennium Management LLC bought a new position in Alzamend Neuro during the fourth quarter valued at $26,000. Geode Capital Management LLC bought a new position in Alzamend Neuro during the fourth quarter valued at $56,000. Finally, Commonwealth Equity Services LLC bought a new position in Alzamend Neuro during the fourth quarter valued at $221,000. Institutional investors and hedge funds own 0.82% of the company’s stock.

About Alzamend Neuro (Get Rating)

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline includes AL001, an ionic cocrystal technology delivering a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's and other neurodegenerative diseases, and psychiatric disorders; and AL002, a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's.

Further Reading